Tesaglitazar.
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
Kamber
Niklaus
N
University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, Fremantle, WA 6959, Australia. nkamber@meddent.uwa.au
Davis
Timothy M E
TM
D000476:Alkanesulfonates / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D047493:PPAR alpha / Q000819:agonists*; D047495:PPAR gamma / Q000819:agonists*; D010330:Patents as Topic; D010666:Phenylpropionates / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000476:Alkanesulfonates; D047493:PPAR alpha; D047495:PPAR gamma; D010666:Phenylpropionates; C501413:tesaglitazar